These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [123I] beta-CIT, a tracer for dopamine and serotonin re-uptake sites: preparation and preliminary SPECT studies in humans.
    Author: Bergström KA, Kuikka JT, Ahonen A, Vanninen E.
    Journal: J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):128-31. PubMed ID: 7632756.
    Abstract:
    beta-CIT (2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane) is a new ligand that has a high affinity to dopamine and serotonin re-uptake sites. [123I] beta-CIT was prepared by reacting the corresponding trimethylstannyl precursor with no-carrier-added 123I. Iodogen was used as an oxidizing agent. The labeling mixture was purified by filtration through a mini-column. The purity of the product was confirmed by analytical HPLC. The total radiochemical yield was 67 +/- 5%. The radiochemical purity was > 95% and the specific activity was > 107 GBq/mol (> 2900 Ci/mmol). The final product was confirmed to be free of endotoxins before intravenous administration. Two healthy male volunteers were injected iv with 120-160 MBq of [123I] beta-CIT and scanned with a 3-head gamma-camera (Siemens MultiSPECT3). Dynamic SPECT scans were performed for up to 2 hours. There was a high accumulation of radioactivity in the striatum and in the thalamus, and some in the medial prefrontal area. Thus, we have developed an easy method to prepare [123I] beta-CIT with a high specific radioactivity and in a sufficient radiochemical yield. Specific [123I] beta-CIT binding in striatal and thalamic regions was demonstrated in humans. [123I] beta-CIT is a potential marker of the dopamine and serotonin transporters and can be used to study the pathophysiology of Parkinson's disease, as well as neuropsychiatric disorders.
    [Abstract] [Full Text] [Related] [New Search]